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Abstract
Down syndrome (DS) or trisomy 21 is the most prevalent chromosomopathy. Interesting associations have been
documented between DS and various hematopoietic and non-hematopoietic malignancies. Transient
myeloproliferative disorder (TMD) is a clonal proliferation of megakaryoblasts, typically occurring in newborns with
DS. It is believed that TMD occurs in the presence of GATA-1 mutation together with trisomy 21. The disorder
resolved in the majority of patients during the first six months of life, however, 30% of patients can develop acute
leukemia or a myelodysplastic syndrome in the first five years of life. In most instances, this unique disorder has the
ability to spontaneously “turn off” the overproliferation and enter a state of remission. Only supportive care is
recommended for TMD during the first months of life unless the clinical condition requires intervention.
This is the report of a preterm newborn with Down syndrome diagnosed with TMD that required chemotherapy on
the first days of life due to a poor clinical course and other risk factors for early death. As more cases of this disorder
are presented, it is important to share our experience to aid in management and diagnosis.
Introduction
Down syndrome or trisomy 21 is the most prevalent
chromosomopathy with an incidence of approximately 1 per 700 live
births. Prevalence correlates with advanced maternal age. More than
95% of cases are secondary to meiotic non-disjunction, and rarely, it
may be due to mosaicism or translocation [1,2]. Interesting
associations have been documented between Down syndrome (DS)
and various hematopoietic and non-hematopoietic malignancies.
Throughout their lives, patients with DS have a reduced overall risk of
solid tumors. In contrast, a 500-fold increased risk of acute
megakaryoblastic leukemia (AMKL) is observed during early
childhood (1-5 years of age) [1-3].
Transient abnormal myelopoiesis (TAM) is seen exclusively in
Down syndrome and affects approximately 4 to 10% of newborns. The
true incidence is unknown since patients may be asymptomatic and it
is not always necessary to perform routine laboratory tests. The
average age of presentation is between 3 to 7 days, but there are
patients diagnosed up to 2 months of age [2]. The pathogenesis of
transient myeloproliferative disorder is complex, with multiple
processes which lead to the presence of megakaryocytic lineage blasts
in peripheral blood of infants with trisomy 21. Although some steps
have been elucidated in this pathway, many remain unknown [1-3].
The development of this disorder seems to require the acquisition of a
somatic mutation of the gene encoding the hematopoietic
transcription factor GATA-1. GATA-1 mutations result in the
expression of a GATA-1 protein truncated at the amino terminus
(GATA1s).The functional consequence is poor megakaryocytic
differentiation and uncontrolled proliferation of a blasto population
[3]. The number of blasts is often higher in the peripheral blood than
in the bone marrow (the site of postnatal hematopoiesis), a finding that
is consistent with the origin of the disorder in the tissues of fetal
hematopoiesis (e.g. fetal liver) [1].
The Transient Myeloproliferative Disorder (TMD) is resolved in the
majority of patients during the first three months of life. In
approximately 20% of cases, after an apparent clinical resolution, acute
myeloid leukemia appears in the first 4 years of life [1,2]. The most
common clinical manifestations include hepatomegaly (60%),
splenomegaly (35%-40%), jaundice (15%), pericardial effusion (15%),
pleural effusion (10%-15%), ascites (10%), respiratory distress (10%)
and hemorrhagic diathesis (10%). Less common features include liver
fibrosis, fetal hydrops and renal failure [1,4,5].
The characteristic hematological findings include leukocytosis
(100000/lL in 20%-30% of cases), thrombocytopenia (40% of cases)
and a greater number of circulating blasts. Approximately 10% to 25%
of patients are asymptomatic; therefore, the diagnosis can be
established as an incidental finding during the laboratory evaluation
for some other cause. Occasionally, the finding of myeloproliferative
syndrome may even be the first indication that a patient has trisomy 21
[1,5]. The diagnosis of TMD is commonly suspected in new-borns
with Down syndrome who have blasts in the peripheral blood smear
and abnormal cell counts [6,7].
When TMD is clinically suspected, a cytogenetic karyotypic analysis
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analysis of the GATA1 mutation is also recommended to document
clones of the blasto population. The presence of a mutation or
mutations acquired in exon 2 or 3 of the GATA1 gene on the X
chromosome establishes a diagnosis of TMD and serves as a potential
marker for the future control of the disease in the development of
AMKL [1,6,8]. Bone marrow examination is usually not indicated
since the findings in it are similar or less pronounced than those in the
blood [6].
The natural history of transient myeloproliferative syndrome is quite
variable. The majority of neonates (80% of those with documented
TMD) experience spontaneous remission within 3 to 6 months of age.
At the other end of the spectrum of the disease, neonatal (or even fetal)
death occurs in approximately 10% of patients secondary to diffuse
organ infiltration by megakaryoblasts, associated parenchymal fibrosis
and subsequent multisystem failure. Approximately 20% of patients
with TMD develop AMKL in their first 4 years of life and this may be
preceded by a myelodysplastic syndrome [1,9].
Independent risk factors that predict early mortality include white
blood cell counts above 100000/lL, premature births (37 weeks),
effusions (pleural, pericardial, ascites or hydrops), coagulopathy,
hemorrhagic diathesis, platelet count greater than 100000/lL, low birth
weight and failure to eliminate peripheral blasts. When these high-risk
characteristics are present, the intervention is justified by
chemotherapy. The cytidine deaminase gene participates in the
catabolism of cytarabine and its transcription decreases in patients
with Down syndrome, which leads to a decrease in the metabolism of
the drug intracellularly with the subsequent increase in the efficacy of
the drug [1,10,11].
It has been shown that a short cycle of low-dose cytarabine
decreases the risk of death in TMD, but does not appear to prevent
progression to acute myeloid leukemia. For infants with one or more
risk factors for early death, cytoreductive therapy should be offered
with low doses of subcutaneous cytarabine (10 mg/m per dose) every
12 h for a total of seven days [9,12-14].
Case Report
Preterm new-born of 35 weeks of post-menstrual age, with
premature rupture of membranes of approximately 7 hours of
evolution, with antecedents of controlled pregnancy with negative
serology, maternal age of 40 years, 4 previous healthy children, with
both healthy parents, not consanguineous. Ultrasound of first and
second trimester without pathological findings, nuchal translusence
within normal range. In third-trimester ultrasound, uterus gestase with
single fetus, live, amniotic fluid in sufficient quantity, fetal
morphological examination with moderate hepatosplenomegaly with
decreased echogenicity of both organs.
A girl of 2225 g, size 43 cm, head circumference 30.5 cm, Apgar 8/8,
with good adaptation to extra-uterine life, without oxygen requirement
is born by vaginal delivery. It presents phenotype compatible with
trisomy 21 and severe hepatosplenomegaly. Neonatal admission is
decided and empirical antibiotic therapy (Ampicillin - Gentamicin)
and parenteral hydration are indicated.
Laboratory was performed and it was observed: erythrocyte 5.24
million/ul, hemoglobin 17.6 g/dl, haematocrit 53.7%, leukocytes
48,100/ul (presence of immature elements, 60 erythroblasts per 100
white blood cells), platelets 280,000/ul, PCR 5 mg/l (VN: <5), GPT 261
U/l, GOT 392 U/l, GGT 585 U/l, FAL 897 U/l.
Interconsultation is carried out with genetic service which takes
samples for karyotype where trisomy 21 is confirmed.
Interconsultation is performed with oncohematology service, who
decides to adopt expectant management and assess clinical and
laboratory evolution.
An echocardiogram is performed where persistent ductus arteriosus
and pulmonary hypertension is reported, cerebral ultrasound showed
marked bilateral symmetric periventricular hyperechogenicity and
abdominal ultrasound showed marked hepatomegaly (crosses the
midline and occupies right hypochondrium), moderate splenomegaly,
hyperechoic kidneys without cysts and gallbladder with biliary mud
inside.
At 24 hours of age, severe indirect hyperbilirubinemia (total
bilirubin 24.85 mg%, bilirubin direct: 2.43 mg%, bilirubin indirect:
22.42 mg%, LDH 16.260 U/l, maternal blood group O+, blood group
of new-born A+) is observed in the laboratory. It requires
phototherapy and exchange-transfusion where two volemias are
replaced. After this procedure, laboratory is checked and
Gammaglobulin EV passage is indicated at 1 g/kg.
At 48 h of age, it begins with haematological alterations and
coagulation disorders (Platelets 51,000/ul, PT 26%, APTT 48
s).Vitamin K EV is indicated and transfusions of fresh frozen plasma
are performed as needed. After a transient improvement, on the sixth
day of life she presents episode of low digestive hemorrhage and
oligoanuria with generalized edema. Doses of furosemide VO (2
mg/kg) were made and it was decided to start with ursodeoxycholic
acid by pattern of persistent cholestasis in the laboratory.
On the ninth day of life it presents a feverish record of 38.4°C. A
sample is taken for uroculture, blood culture and retro-culture of
central venous access and empirical antibiotic therapy is started with
Vancomycin+Amikacin EV. The girl evolves unfavorably, with greater
respiratory effort that worsens with the passing of hours, active
bleeding by high digestive tract with fresh blood debits in moderate
amount. She presented impending respiratory claudication, so
intubation with TET No. 3 was decided, it was placed in mechanic
ventilation (mode pressure controlled ventilation) and inotropic
support was started at high doses due to refractory hypotension
(Adrenaline, Dopamine, Hydrocortisone). She required TET
replacement due to total obstruction with blood and secretions.
Cerebral ultrasound is repeated where grade II intraventricular
hemorrhage is reported and abdominal ultrasound shows ascites,
hepatosplenomegaly, globular kidneys with normal Doppler,
significant persistent ductus arteriosus. On the tenth day of life she
presents pulmonary hemorrhage and coagulopathy that requires
transfusions with cryoprecipitates and fresh frozen plasma every 8 h.
Due to a poor clinical course, with hyperleukocytosis in the laboratory
(leukocytes 137,400/ul), chemotherapy with Citarabine EV 8 mg/day
was decided jointly with the oncohematology service.
At 11 days of age, urocultureinformed no inflammatory response,
with development of gram-negative bacillus (Klebsiella pneumoniae
BLEE). It was decided to rotate therapeutic scheme to Vancomycin
+Meropenem EV. At 14 days of age the girl presents a cardiac arrest.
Advanced resuscitation is performed for 15 min without obtaining
favorable response, declaring her death.
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Discussion
Neonatal TMD is considered a serious disease requiring intensive
care shortly after birth. As such, diagnosis and assessment of its
severity must be immediate. Without cordocentesis, prenatal diagnosis
is very difficult. Two cases of fetal TAM were reported that were
diagnosed on the basis of ultrasonographic evidence of hydrops and
hepatosplenomegaly. There was the first published report suggesting a
relation between fetal TMD and hepatosplenomegaly. Smrcek and
colleagues showed in a retrospective study that fetal
hepatosplenomegaly and/or hydrops in the second half of pregnancy is
a sign of myeloproliferative disorder in fetuses with trisomy 21 or
mosaic trisomy [15].
Fetal hepatomegaly is a specific finding in cases of severe
isoimmunization disorder, in utero infection, fetal congestive heart
failure, and metabolic disorder. If these conditions are excluded then
fetal hepatomegaly associated with Down syndrome should be
regarded as diagnostic of TMD and an indication for the need to
prepare for neonatal intensive care [15]. In previous case series, TMD
was found to have a high case fatality rate, despite the generally
accepted approach of supportive care until the disease's spontaneous
resolution. This has led to significant confusion and unease among
clinicians as to the proper route of action when a patient with TMD
presents [8]. In the Children's Oncology Group Study A2971, 78% of
children with TMD had mild symptoms and spontaneous resolution of
their disease without intervention, similar to a recent report from the
BFM (84%). This ranged from those who only had transient blasts in
the peripheral blood (31%) to those with mild organomegaly, such as
hepatomegaly (58%), abnormal liver function studies (41%), and
splenomegaly (36%), similar to other recent reports. In comparison,
those patients who presented in moribund condition or with lisis
tumoral syndrome were likely to lead to mortality if intervention is not
implemented. Organ infiltration, primarily hepatic, may be severe,
progressive, and fatal. Hayashi et al found 10 of 15 TMD patients died
within the first few months of disseminated intravascular coagulation,
hepatic failure, or renal failure. Zipursky et al. [3] identified 7 of 13
severe TMD patients in the literature died, of whom 5 were stillborn,
and 2 died later. Hydrops fetalis was a predominant symptom in these
patients, with prominent blast infiltration of the heart and liver found
at autopsy with associated fibrosis, whereas none of these findings were
found in the marrow. Three of the 4 reviewed patients died within 24 h
of birth [8]. Subsequently, Al-Kasim et al. [14] further described the
central role of hepatic involvement in those with a fatal outcome. Nine
of 48 patients enrolled had life-threatening disease, 7 with hepatic
fibrosis and 2 with cardiorespiratory failure. Without intervention all
died, whereas 3 children in whom short courses of low-dose cytarabine
were administered survived. More recently, Klusmann et al. [12]
reported the BFM registry experience, which identified that high-risk
patients (high WBC, prematurity, ascites, and failure of TMD
resolution) had an improved outcome if intervention was given (72%
vs. 24%, P=0.001). Intervention clearly appears to have a role in
supporting these children through a critical period of their disease [6].
Because of this wide range of presentations and their incumbent
mortality risks, it is important to better ascertain who may require
intervention before spontaneous resolution. The Children's Oncology
Group Study A2971 proposes a mortality risk-based classification
system to stratify the treatment of TMD patients. They identified 3
distinct TMD risk groups. High-risk patients have early evidence of
LTS and a TMD-associated mortality rate of 55% at 3 years. Most
infants with TMD (41%) belong to the intermediate-risk group,
specifically those with hepatomegaly although without LTS. These
infants rarely die from acute complications of TMD; however, they
have a 23% 3 year mortality rate. This is double the overall mortality
rate of the low risk group and is disproportionately greater than the
mortality rates of DS infants without TMD. The rest (38%) are the
classic “low-risk” patients in whom the disease spontaneously resolves
without therapeutic intervention. Low-risk patients have less than a
2.3% chance of dying from acute complications of TMD [8].
Conclusion
Transient myeloproliferative syndrome, also called transient
neonatal leukemia or transient anomalous myelopoiesis, is described in
most cases in new-borns with trisomy 21. The approximate incidence
is 10% [7,13]. The disorder is detected in approximately 80% of the
cases in the third trimester, and in the rest of the cases it is performed
postpartum. Among the suggestive echographic findings, it can be
noted: hepatosplenomegaly (79.5%), fetal hydrops (30.8%), pericardial
effusion (23.1%) and alteration in the volume of amniotic fluid
(15.4%). Prenatal diagnosis requires high presumption and diagnostic
suspicion and therefore the prognosis is worse, and it has high
mortality [16]. Its clinical expression is variable, although there are
asymptomatic cases, other patients present symptoms caused by organ
infiltration or tumor lysis, accompanied by intense leukocytosis,
leukostasis, organic failure with hemodynamic and respiratory
compromise [7,17]. The circulating blasts in the peripheral blood
exhibit immunophenotypic markers of myeloblastic, megarioblastic
and erythroblastic precursors. The clinical course is usually self-
limiting during the first six months. However, 30% of patients can
develop acute leukemia (MAM-M7) or a myelodysplastic syndrome in
the first five years of life [14,16].
It is important to make a differential diagnosis with other entities
that have leukemoid reactions, thrombocytopenia and anemia, such as
congenital viral infections (TORCH), neonatal hemolytic processes
(Rh incompatibility), neonatal leukemia, histiocytosis, neuroblastoma
or situations that occur with perinatal hypoxia [9,11,18].
The initial treatment is supportive therapy. Chemotherapy is used in
patients with severe manifestations, such as compromised liver or
cardiorespiratory function that are accompanied by visceromegaly or
serous effusion, as well as severe leukocytosis [19]. The actual
incidence of TAM is difficult to determine without performing a
prospective screening of all infants with down syndrome. Although the
diagnosis of TMD is usually made with clinical and haematological
findings, molecular diagnosis by demonstrating the GATA1
mutation(s) will clarify the diagnosis in clinical and hematologically
silent cases [17]. Given the variable clinical presentation of TAM, it is
important to identify the factors that reliably predict the outcome and,
therefore, the patients who are likely to benefit from the treatment. It
will also be important to consider which babies deserve treatment and
to establish the most effective treatment regimens [14,17].
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